“South Africa has been a target country for many multinational pharmaceutical and biotech companies in recent years. Its well established clinical research industry with a Medical Control Council (MCC) that operates to FDA and ICH standards, as well as its high patient population, has led to an increase in clinical trials in the region. Serving as a gateway to Sub Saharan Africa, this large patient population is ideal for clinical trials studying bacterial and fungal diseases, cancers, immune system and respiratory tract diseases.
Established in 2009, Fisher Clinical Services South Africa has recently expanded to accommodate the needs of our clients, serving the large clinical trial patient population of South Africa and Sub Saharan Africa.
In August 2017 the MCC approved Fisher Clinical Services South Africa as the first regulatory licenced service provider to be able to perform dedicated secondary packaging and labeling for clinical trials in South Africa. This is a great accolade as it further positions our local team to support clinical research in this region. Ngiyabonga (thank you) to our local team for their hard work and dedication in preparing our facility to receive this new licence!
We invite you to find out more about our facility.”
Dennis Bode General Manager, Fisher Clinical Services, South Africa
Fast Facts on the Region:
- Africa is the second largest continent in the world in both area and population. It covers circa 20% of the Earth’s total land area
- Africa has circa 1,072m inhabitants in 54 countries, accounting for 14% of the world’s population
- The population of Sub Saharan Africa was estimated at 874m in 2011. South Africa serves as a hub to Sub Saharan Africa
- Access to a patient population for diseases prevalent to the region such as tuberculosis, malaria and HIV/AIDS, and to other diseases also prevalent in the developed world such as cancer, hypertension and diabetes
- Potential to run low-cost clinical trials